Cargando…

Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study

Continuous infusion of beta-lactam antibiotics has emerged as an alternative for the treatment of sepsis because of the favourable pharmacokinetics of continuous infusion. This study aimed to evaluate the survival benefits of continuous vs. intermittent infusion of piperacillin-tazobactam in critica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Dong-gon, Seo, Jarim, Lee, Su Yeon, Ahn, Jee Hwan, Hong, Sang-Bum, Lim, Chae-Man, Koh, Younsuck, Huh, Jin Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686508/
https://www.ncbi.nlm.nih.gov/pubmed/36358163
http://dx.doi.org/10.3390/antibiotics11111508
_version_ 1784835766664298496
author Hyun, Dong-gon
Seo, Jarim
Lee, Su Yeon
Ahn, Jee Hwan
Hong, Sang-Bum
Lim, Chae-Man
Koh, Younsuck
Huh, Jin Won
author_facet Hyun, Dong-gon
Seo, Jarim
Lee, Su Yeon
Ahn, Jee Hwan
Hong, Sang-Bum
Lim, Chae-Man
Koh, Younsuck
Huh, Jin Won
author_sort Hyun, Dong-gon
collection PubMed
description Continuous infusion of beta-lactam antibiotics has emerged as an alternative for the treatment of sepsis because of the favourable pharmacokinetics of continuous infusion. This study aimed to evaluate the survival benefits of continuous vs. intermittent infusion of piperacillin-tazobactam in critically ill patients with sepsis. We retrospectively conducted a single-centre study of continuous infusion vs. intermittent infusion of piperacillin-tazobactam for adult patients who met the Sepsis-3 criteria and were treated at a medical ICU within 48 h after hospitalisation between 1 May 2018 and 30 April 2020. The primary outcome was mortality at 28 days. A total of 157 patients (47 in the continuous group and 110 in the intermittent group) met the inclusion criteria for evaluation. The 28-day mortality rates were 12.8% in the continuous group and 27.3% in the intermittent group (p = 0.07). However, after adjustment for potential covariables, patients in the continuous group (12.8%) showed significantly lower mortality at 28 days than those in the intermittent group (27.3%; adjusted hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.13–0.79; p = 0.013). In sepsis patients, continuous infusion of piperacillin-tazobactam may confer a benefit regarding the avoidance of mortality at 28 days compared with intermittent infusion.
format Online
Article
Text
id pubmed-9686508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96865082022-11-25 Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study Hyun, Dong-gon Seo, Jarim Lee, Su Yeon Ahn, Jee Hwan Hong, Sang-Bum Lim, Chae-Man Koh, Younsuck Huh, Jin Won Antibiotics (Basel) Article Continuous infusion of beta-lactam antibiotics has emerged as an alternative for the treatment of sepsis because of the favourable pharmacokinetics of continuous infusion. This study aimed to evaluate the survival benefits of continuous vs. intermittent infusion of piperacillin-tazobactam in critically ill patients with sepsis. We retrospectively conducted a single-centre study of continuous infusion vs. intermittent infusion of piperacillin-tazobactam for adult patients who met the Sepsis-3 criteria and were treated at a medical ICU within 48 h after hospitalisation between 1 May 2018 and 30 April 2020. The primary outcome was mortality at 28 days. A total of 157 patients (47 in the continuous group and 110 in the intermittent group) met the inclusion criteria for evaluation. The 28-day mortality rates were 12.8% in the continuous group and 27.3% in the intermittent group (p = 0.07). However, after adjustment for potential covariables, patients in the continuous group (12.8%) showed significantly lower mortality at 28 days than those in the intermittent group (27.3%; adjusted hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.13–0.79; p = 0.013). In sepsis patients, continuous infusion of piperacillin-tazobactam may confer a benefit regarding the avoidance of mortality at 28 days compared with intermittent infusion. MDPI 2022-10-29 /pmc/articles/PMC9686508/ /pubmed/36358163 http://dx.doi.org/10.3390/antibiotics11111508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hyun, Dong-gon
Seo, Jarim
Lee, Su Yeon
Ahn, Jee Hwan
Hong, Sang-Bum
Lim, Chae-Man
Koh, Younsuck
Huh, Jin Won
Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title_full Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title_fullStr Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title_full_unstemmed Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title_short Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
title_sort continuous piperacillin-tazobactam infusion improves clinical outcomes in critically ill patients with sepsis: a retrospective, single-centre study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686508/
https://www.ncbi.nlm.nih.gov/pubmed/36358163
http://dx.doi.org/10.3390/antibiotics11111508
work_keys_str_mv AT hyundonggon continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT seojarim continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT leesuyeon continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT ahnjeehwan continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT hongsangbum continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT limchaeman continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT kohyounsuck continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy
AT huhjinwon continuouspiperacillintazobactaminfusionimprovesclinicaloutcomesincriticallyillpatientswithsepsisaretrospectivesinglecentrestudy